Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-05-26
1999-12-14
Fan, Jane
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514318, 514332, 514356, 546194, 546263, 546321, 544365, C07D40110, A61K 31445
Patent
active
060018364
ABSTRACT:
A series of non-peptidergic antagonists of NPY have been synthesized and are comprised of cyanoguanidine derivatives of 4-phenyl-1,4-dihydropyridines of Formula (I). ##STR1## As antagonists of NPY-induced feeding behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.
REFERENCES:
patent: 4829076 (1989-05-01), Szilagyi et al.
patent: 5554621 (1996-09-01), Poindexter et al.
patent: 5635503 (1997-06-01), Poindexter et al.
patent: 5668151 (1997-09-01), Poindexter et al.
David Alker, et al., "Long-Acting Dihydropyridine Calcium Antagonists. 4. Synthesis and Structure-Activity Relationships for a Series of Basic and Nonbasic Derivatives of 2-[(2-Aminoethoxy)methyl]-1,4-dihydropyridine Calcium Antagonists," J. Med. Chem., 1990, 33, 585-591.
Breitenbucher James Guy
Bruce Marc A.
Huang Yazhong
Morton Mendi A.
Poindexter Graham S.
Bristol--Myers Squibb Company
Fan Jane
Ryan Richard P.
LandOfFree
Dihydropyridine NPY antagonists: cyanoguanidine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dihydropyridine NPY antagonists: cyanoguanidine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dihydropyridine NPY antagonists: cyanoguanidine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-863652